Karyotype evolution of Ph positive chronic myelogenous leukemia patients relapsed in advanced phases of the disease after allogeneic bone marrow transplantation

Mario Sessarego, Francesco Frassoni, Raffaella Defferrari, Andrea Bacigalupo, Giuseppina Fugazza, Cristina Mareni, Roberto Bruzzone, Anna Dejana, Franco Ajmar

Research output: Contribution to journalArticle

Abstract

Sixty-eight patients affected by Philadelphia chromosome (Ph) positive chronic myelogenous leukemia (CML) underwent allogeneic bone marrow transplantation (BMT) and were successfully studied from a cytogenetic point of view, before and after the BMT. Nineteen had evidence of cytogenetic and clinical relapse. Cytogenetic analyses of 14 patients who, after the relapse, showed progression to the accelerated or blastic phase of the disease, are presented. Five of these cases had only the Ph chromosome without karyotype evolution; in one case Ph duplication without other anomalies was detected, while in the remaining eight cases cytogenetic analysis showed apparently random clonal structural abnormalities (translocations, inversions, deletions, and marker formations). Therefore, the classical "non-random" abnormalities (+8, i(17q), +Ph, +19, +21) were not as common as in conventionally treated Ph+ CML. From our data, karyotype evolution during advanced phases in Ph+ CML patients after BMT differs from the evolution seen in conventionally treated patients, by the presence of numerous structural unusual abnormalities, possibly related to radiochemotherapy conditioning to BMT. Therefore, BMT treatment is not always able to eradicate the Ph+ clone but can reduce the incidence of the formation and/or expansion of Ph+ clones with additional non-random abnormalities.

Original languageEnglish
Pages (from-to)69-78
Number of pages10
JournalCancer Genetics and Cytogenetics
Volume57
Issue number1
DOIs
Publication statusPublished - 1991

Fingerprint

Homologous Transplantation
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bone Marrow Transplantation
Karyotype
Cytogenetic Analysis
Cytogenetics
Clone Cells
Recurrence
Philadelphia Chromosome
Chemoradiotherapy
Chromosomes
Incidence

ASJC Scopus subject areas

  • Cancer Research
  • Genetics
  • Molecular Biology

Cite this

Karyotype evolution of Ph positive chronic myelogenous leukemia patients relapsed in advanced phases of the disease after allogeneic bone marrow transplantation. / Sessarego, Mario; Frassoni, Francesco; Defferrari, Raffaella; Bacigalupo, Andrea; Fugazza, Giuseppina; Mareni, Cristina; Bruzzone, Roberto; Dejana, Anna; Ajmar, Franco.

In: Cancer Genetics and Cytogenetics, Vol. 57, No. 1, 1991, p. 69-78.

Research output: Contribution to journalArticle

Sessarego, Mario ; Frassoni, Francesco ; Defferrari, Raffaella ; Bacigalupo, Andrea ; Fugazza, Giuseppina ; Mareni, Cristina ; Bruzzone, Roberto ; Dejana, Anna ; Ajmar, Franco. / Karyotype evolution of Ph positive chronic myelogenous leukemia patients relapsed in advanced phases of the disease after allogeneic bone marrow transplantation. In: Cancer Genetics and Cytogenetics. 1991 ; Vol. 57, No. 1. pp. 69-78.
@article{54826c28ee114c3098a6e689130e5bad,
title = "Karyotype evolution of Ph positive chronic myelogenous leukemia patients relapsed in advanced phases of the disease after allogeneic bone marrow transplantation",
abstract = "Sixty-eight patients affected by Philadelphia chromosome (Ph) positive chronic myelogenous leukemia (CML) underwent allogeneic bone marrow transplantation (BMT) and were successfully studied from a cytogenetic point of view, before and after the BMT. Nineteen had evidence of cytogenetic and clinical relapse. Cytogenetic analyses of 14 patients who, after the relapse, showed progression to the accelerated or blastic phase of the disease, are presented. Five of these cases had only the Ph chromosome without karyotype evolution; in one case Ph duplication without other anomalies was detected, while in the remaining eight cases cytogenetic analysis showed apparently random clonal structural abnormalities (translocations, inversions, deletions, and marker formations). Therefore, the classical {"}non-random{"} abnormalities (+8, i(17q), +Ph, +19, +21) were not as common as in conventionally treated Ph+ CML. From our data, karyotype evolution during advanced phases in Ph+ CML patients after BMT differs from the evolution seen in conventionally treated patients, by the presence of numerous structural unusual abnormalities, possibly related to radiochemotherapy conditioning to BMT. Therefore, BMT treatment is not always able to eradicate the Ph+ clone but can reduce the incidence of the formation and/or expansion of Ph+ clones with additional non-random abnormalities.",
author = "Mario Sessarego and Francesco Frassoni and Raffaella Defferrari and Andrea Bacigalupo and Giuseppina Fugazza and Cristina Mareni and Roberto Bruzzone and Anna Dejana and Franco Ajmar",
year = "1991",
doi = "10.1016/0165-4608(91)90191-V",
language = "English",
volume = "57",
pages = "69--78",
journal = "Cancer Genetics and Cytogenetics",
issn = "0165-4608",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Karyotype evolution of Ph positive chronic myelogenous leukemia patients relapsed in advanced phases of the disease after allogeneic bone marrow transplantation

AU - Sessarego, Mario

AU - Frassoni, Francesco

AU - Defferrari, Raffaella

AU - Bacigalupo, Andrea

AU - Fugazza, Giuseppina

AU - Mareni, Cristina

AU - Bruzzone, Roberto

AU - Dejana, Anna

AU - Ajmar, Franco

PY - 1991

Y1 - 1991

N2 - Sixty-eight patients affected by Philadelphia chromosome (Ph) positive chronic myelogenous leukemia (CML) underwent allogeneic bone marrow transplantation (BMT) and were successfully studied from a cytogenetic point of view, before and after the BMT. Nineteen had evidence of cytogenetic and clinical relapse. Cytogenetic analyses of 14 patients who, after the relapse, showed progression to the accelerated or blastic phase of the disease, are presented. Five of these cases had only the Ph chromosome without karyotype evolution; in one case Ph duplication without other anomalies was detected, while in the remaining eight cases cytogenetic analysis showed apparently random clonal structural abnormalities (translocations, inversions, deletions, and marker formations). Therefore, the classical "non-random" abnormalities (+8, i(17q), +Ph, +19, +21) were not as common as in conventionally treated Ph+ CML. From our data, karyotype evolution during advanced phases in Ph+ CML patients after BMT differs from the evolution seen in conventionally treated patients, by the presence of numerous structural unusual abnormalities, possibly related to radiochemotherapy conditioning to BMT. Therefore, BMT treatment is not always able to eradicate the Ph+ clone but can reduce the incidence of the formation and/or expansion of Ph+ clones with additional non-random abnormalities.

AB - Sixty-eight patients affected by Philadelphia chromosome (Ph) positive chronic myelogenous leukemia (CML) underwent allogeneic bone marrow transplantation (BMT) and were successfully studied from a cytogenetic point of view, before and after the BMT. Nineteen had evidence of cytogenetic and clinical relapse. Cytogenetic analyses of 14 patients who, after the relapse, showed progression to the accelerated or blastic phase of the disease, are presented. Five of these cases had only the Ph chromosome without karyotype evolution; in one case Ph duplication without other anomalies was detected, while in the remaining eight cases cytogenetic analysis showed apparently random clonal structural abnormalities (translocations, inversions, deletions, and marker formations). Therefore, the classical "non-random" abnormalities (+8, i(17q), +Ph, +19, +21) were not as common as in conventionally treated Ph+ CML. From our data, karyotype evolution during advanced phases in Ph+ CML patients after BMT differs from the evolution seen in conventionally treated patients, by the presence of numerous structural unusual abnormalities, possibly related to radiochemotherapy conditioning to BMT. Therefore, BMT treatment is not always able to eradicate the Ph+ clone but can reduce the incidence of the formation and/or expansion of Ph+ clones with additional non-random abnormalities.

UR - http://www.scopus.com/inward/record.url?scp=0026337875&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026337875&partnerID=8YFLogxK

U2 - 10.1016/0165-4608(91)90191-V

DO - 10.1016/0165-4608(91)90191-V

M3 - Article

C2 - 1756487

AN - SCOPUS:0026337875

VL - 57

SP - 69

EP - 78

JO - Cancer Genetics and Cytogenetics

JF - Cancer Genetics and Cytogenetics

SN - 0165-4608

IS - 1

ER -